Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study

Javier Trujillo-Santos ¹, Ignacio García-Escobar ², Mercedes Salgado ³

¹Internal Medicine Department, Santa Lucía General University Hospital, Catholic University of Murcia, 30202 Murcia, Spain.
²Medical Oncology Department, General University Hospital of Toledo, 45007 Toledo, Spain.
³Medical Oncology Department, Ourense University Hospital Complex, 32005 Ourense, Spain.
⁴Santo António University Hospital Centre, School of Medicine and Biomedical Sciences (ICBAS), University of Porto, 4099-001 Porto, Portugal.
⁵Medical Oncology Service, Marqués de Valdecilla University Hospital, Valdecilla Research Institute (IDIVAL), 39008 Santander, Spain.
⁶Medical Oncology Department, Príncipe de Asturias Teaching Hospital, 28805 Alcalá de Henares, Spain.
⁷Medical Oncology Department, Torrecárdenas University Hospital, 04009 Almería, Spain.
⁸Haematology Service, Bellvitge University Hospital, 08907 Barcelona, Spain.
⁹Medical Oncology Service, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute (I3PT-CERCA), Autonomous University of Barcelona, 08208 Sabadell, Spain.
¹⁰Medical Affairs Department, LEO Pharma, 08003 Barcelona, Spain.
¹¹Biostatistics Unit, Medical School, Autonomous University of Barcelona, 08193 Barcelona, Spain.
¹²Medical Oncology Department, Mútua de Terrassa Hospital, 08221 Barcelona, Spain.
¹³Medical Oncology Department, Catalan Institute of Oncology (ICO), 17007 Girona, Spain.
¹⁴Medical Oncology Department, General University Hospital, 46014 Valencia, Spain.
¹⁵Medical Oncology, São Francisco Xavier Hospital, Lisboa Ocidental Hospital Centre (CHLO), 1449-005 Lisbon, Portugal.
¹⁶Medical Oncology Department, Clinic Hospital, 08036 Barcelona, Spain.
¹⁷Translational Medical Oncology Group, Oncomet, Santiago de Compostela University Hospital Complex (CHUS), 15706 Santiago de Compostela, Spain.
¹⁸Galdakao Hospital, 48960 Galdakao, Spain.
¹⁹Oncology Division, Santa Maria Hospital, Lisboa Norte Hospital Centre (CHLN), 1649-028 Lisbon, Portugal.
²⁰Medical Oncology Department, Setúbal Hospital Centre, 2910-446 Setúbal, Portugal.
²¹Medical Oncology Department, Virgen de la Arrixaca Clinical University Hospital, 30120 Murcia, Spain.

⁰Internal Medicine Department, Santa Lucía General University Hospital, Catholic University of Murcia, 30202 Murcia, Spain.

The Oncologist +

|

December 14, 2024

View abstract on PubMed

Summary

The CARTAGO model identifies cancer patients at high risk for venous thromboembolism (VTE). This tool helps select ambulatory patients who may benefit from primary thromboprophylaxis to prevent VTE.

Area Of Science

Oncology
Hematology
Vascular Medicine

Background

Venous thromboembolism (VTE) is a significant cause of mortality in cancer patients.
There is a need for accessible risk assessment tools to guide VTE prophylaxis in oncology.
Identifying patients who benefit from primary thromboprophylaxis is crucial.

Purpose Of The Study

To develop a predictive model for assessing VTE risk in cancer patients undergoing specific treatments.
To create an easily applicable tool for clinical use in outpatient settings.

Main Methods

A prospective, observational, multicenter study involving 1596 cancer patients across 62 sites in Spain and Portugal.
Development of a predictive model using a competitive risk framework.
Analysis of data collected between January 2018 and December 2019.

Main Results

A total of 1596 patients were analyzed, with 8% experiencing VTE events over 6 months.
The CARTAGO model identified four key predictive variables: tumor type, D-dimer levels, tumor compression of a vessel, and leukocyte count.
The model demonstrated moderate predictive accuracy (C-statistic, 0.646) with significant risk associated with 'very high risk' tumors.

Conclusions

The CARTAGO model effectively predicts VTE risk in ambulatory cancer patients receiving anticancer therapy.
This model can assist clinicians in identifying patients who would likely benefit from primary thromboprophylaxis.
The study provides a valuable tool for proactive VTE management in cancer care.

Keywords:

D-dimer cancer leukocytes thromboprophylaxis venous thromboembolism

Related Concept Videos

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...